These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9425382)

  • 1. A comparison of two amikacin dosing regimens in paediatric surgical patients.
    Forsyth NB; Botha JH; Hadley GP
    Ann Trop Paediatr; 1997 Sep; 17(3):253-61. PubMed ID: 9425382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections.
    Karachalios GN; Houpas P; Tziviskou E; Papalimneou V; Georgiou A; Karachaliou I; Halkiadaki D
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):561-4. PubMed ID: 9799062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
    Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
    J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
    Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens.
    Marik PE; Havlik I; Monteagudo FS; Lipman J
    J Antimicrob Chemother; 1991 May; 27 Suppl C():81-9. PubMed ID: 1856148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients.
    Marik PE; Lipman J; Kobilski S; Scribante J
    J Antimicrob Chemother; 1991 Nov; 28(5):753-64. PubMed ID: 1778878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
    Charnas R; Lüthi AR; Ruch W
    Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity.
    Langhendries JP; Battisti O; Bertrand JM; François A; Darimont J; Ibrahim S; Tulkens PM; Bernard A; Buchet JP; Scalais E
    Dev Pharmacol Ther; 1993; 20(3-4):220-30. PubMed ID: 7828457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review.
    Jenkins A; Thomson AH; Brown NM; Semple Y; Sluman C; MacGowan A; Lovering AM; Wiffen PJ;
    J Antimicrob Chemother; 2016 Oct; 71(10):2754-9. PubMed ID: 27494904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once versus twice daily amikacin in neonates: prospective study on toxicity.
    Kotze A; Bartel PR; Sommers DK
    J Paediatr Child Health; 1999 Jun; 35(3):283-6. PubMed ID: 10404451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ototoxicity and pharmacokinetically determined dosages of amikacin in granulocytopenic cancer patients.
    Danhauer FJ; Fortner CL; Schimpff SC; deJongh CA; Wesley MN; Wiernik PH
    Clin Pharm; 1982; 1(6):539-43. PubMed ID: 7185540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoglycoside dosages and nephrotoxicity: quantitative relationships.
    Rougier F; Ducher M; Maurin M; Corvaisier S; Claude D; Jelliffe R; Maire P
    Clin Pharmacokinet; 2003; 42(5):493-500. PubMed ID: 12739987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic dosing of aminoglycosides: a controlled trial.
    Bartal C; Danon A; Schlaeffer F; Reisenberg K; Alkan M; Smoliakov R; Sidi A; Almog Y
    Am J Med; 2003 Feb; 114(3):194-8. PubMed ID: 12637133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind study of the efficacy and safety of multiple daily doses of amikacin versus one daily dose for children with perforated appendicitis in Costa Rica.
    Pérez V; Saénz D; Madriz J; Harhay M; Feoli J; Castro M; Odio C
    Int J Infect Dis; 2011 Aug; 15(8):e569-75. PubMed ID: 21733727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of the safety of isepamicin in adults.
    Blum D
    J Chemother; 1995 Jun; 7 Suppl 2():87-93. PubMed ID: 8622116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. Scandinavian Amikacin Once Daily Study Group.
    Maller R; Ahrne H; Holmen C; Lausen I; Nilsson LE; Smedjegård J
    J Antimicrob Chemother; 1993 Jun; 31(6):939-48. PubMed ID: 8360131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dosing aminoglycosides once a day].
    Blaser J
    Schweiz Med Wochenschr Suppl; 1996; 76():39S-48S. PubMed ID: 8677418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe gram-negative infections.
    Kafetzis DA; Sianidou L; Vlachos E; Davros J; Baïramis T; Papandreou Y; Paraskaki E; Scouroliakou M; Hadzis A; Papadatos J
    J Antimicrob Chemother; 1991 May; 27 Suppl C():105-12. PubMed ID: 1906861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminoglycoside ototoxicity.
    Matz GJ
    Am J Otolaryngol; 1986; 7(2):117-9. PubMed ID: 3485932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of 'high-dose' amikacin in children.
    Kumor KM; McDonald JM; Lietman PS
    Dev Pharmacol Ther; 1984; 7(6):368-76. PubMed ID: 6518944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.